Press Release 2015

Sabinsa Corporation, the world leader in Curcumin and other fine ingredients for the dietary supplement industry, has successfully concluded its Patent Infringement lawsuit against the second of four companies it filed suit against in the US District Court, New Jersey on July 30, 2014. The lawsuit alleged HerbaKraft, Inc. was selling products that infringed upon Sabinsa’s Curcumin C3 Complex® US Patent 5,861,415 (“the ’415 Patent”), which protects compositions, methods of use, and methods of extraction of a nutritional supplement in the US.

HerbaKraft has agreed, in addition to any undisclosed monetary settlement, to discontinue any and all future sales of Curcumin to outside distribution. The proposed Final Consent Judgment stipulates that the ’415 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office.

Last month Sabinsa announced it had reached a settlement with Prakruti Products Private Limited. In the United States, Sabinsa continues to litigate the willful infringement of the ’415 patent by NutriBioLink LLC, and Olive Lifesciences Private Limited. In Germany, Sabinsa continues to litigate a European Curcumin patent infringed by Olive Lifesciences.

"As we continue to make objection to infringement on our patents crystal clear, such settlements as this and the previous settlement with Prakruti should serve as a deterrent to others contemplating such IP theft,” said Sabinsa Founder Dr. Muhammed Majeed. “Other companies may not sell imitations of Sabinsa’s unique compositions, nor market it for its antioxidant use, nor use the Ethyl Acetate extraction method developed by Sabinsa and outlined in Sabinsa’s patent.”

"We have seen another infringer succumb when confronted with the reality of litigation,” said James H. Hulme, Partner, Arent Fox LLP, the attorney who represents Sabinsa in IP infringement matters. “Sabinsa has invested heavily in its intellectual property, and the courts will protect that investment when presented with a clear infringement claim.”

Curcumin C3 Complex® is a Registered Trademark and Patented product of Sabinsa Corp., and is protected under U.S. Patent No. 5,861,415, and International Patents and Patents Pending. The name C3 Complex was chosen to represent the ingredient’s three main chemical compounds: Curcumin, Demethoxycurcumin & Bisdemethoxycurcumin, collectively known as Curcuminoids. Curcumin C3 Complex® is a specific mixture of Curcuminoids, making it a unique form of Curcumin quite different from generic Curcumin extracts. It has been used in more clinical studies than any other Curcumin ingredient in the world. For more information, visit www.sabinsa.com and www.curcuminoids.com.

    HEADQUARTERS

  • Unit no.1200, 2nd Floor,
    Citiview Building
    12 Mac Dinh Chi Street
    Dakao Ward, District 1
    Hochiminh City 700000
    Vietnam

  • +84(28) 3930 0341
  • +84(28) 3930 0342
  • info@sabinsa.vn

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.